141 related articles for article (PubMed ID: 36202183)
1. Difelikefalin, a peripherally restricted KOR (kappa opioid receptor) agonist, produces diuresis through a central KOR pathway.
Meariman JK; Sutphen JC; Gao J; Mercante DE; Kapusta DR
Pharmacol Res; 2022 Nov; 185():106470. PubMed ID: 36202183
[TBL] [Abstract][Full Text] [Related]
2. Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics.
Meariman JK; Sutphen JC; Gao J; Kapusta DR
Hypertension; 2022 Feb; 79(2):379-390. PubMed ID: 34852633
[TBL] [Abstract][Full Text] [Related]
3. Kappa Opioid Agonist-Induced Diuresis: Characteristics, Mechanisms, and Beyond.
Inan S
Handb Exp Pharmacol; 2022; 271():401-417. PubMed ID: 33483878
[TBL] [Abstract][Full Text] [Related]
4. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor.
Schattauer SS; Kuhar JR; Song A; Chavkin C
Cell Signal; 2017 Apr; 32():59-65. PubMed ID: 28088389
[TBL] [Abstract][Full Text] [Related]
5. Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.
Townsend EA
Psychopharmacology (Berl); 2021 Apr; 238(4):1017-1028. PubMed ID: 33404739
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons.
Jamshidi RJ; Sullivan LC; Jacobs BA; Chavera TA; Berg KA; Clarke WP
J Pharmacol Exp Ther; 2016 Nov; 359(2):319-328. PubMed ID: 27605628
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Kappa Opioid Receptor Inactivation Depends on Sex and Cellular Site of Antagonist Action.
Reichard KL; Newton KA; Rivera ZMG; Sotero de Menezes PM; Schattauer SS; Land BB; Chavkin C
Mol Pharmacol; 2020 Nov; 98(5):548-558. PubMed ID: 32913138
[TBL] [Abstract][Full Text] [Related]
8. Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.
Inan S; Dun NJ; Cowan A
Molecules; 2021 Sep; 26(18):. PubMed ID: 34576988
[TBL] [Abstract][Full Text] [Related]
9. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
[TBL] [Abstract][Full Text] [Related]
10. Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.
Inan S; Cowan A
Handb Exp Pharmacol; 2022; 271():275-292. PubMed ID: 33296031
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the diuretic effects of chemically diverse kappa opioid agonists in rats: nalfurafine, U50,488H, and salvinorin A.
Inan S; Lee DY; Liu-Chen LY; Cowan A
Naunyn Schmiedebergs Arch Pharmacol; 2009 Mar; 379(3):263-70. PubMed ID: 18925386
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.
Dunn A; Windisch K; Ben-Ezra A; Pikus P; Morochnik M; Erazo J; Reed B; Kreek MJ
Psychopharmacology (Berl); 2020 Aug; 237(8):2405-2418. PubMed ID: 32435819
[TBL] [Abstract][Full Text] [Related]
13. 14-3-3γ mediates the long-term inhibition of peripheral kappa opioid receptor antinociceptive signaling by norbinaltorphimine.
Wedemeyer MJ; Jennings EM; Smith HR; Chavera TS; Jamshidi RJ; Berg KA; Clarke WP
Neuropharmacology; 2022 Dec; 220():109251. PubMed ID: 36126728
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between
Cao D; Huang P; Chiu YT; Chen C; Wang H; Li M; Zheng Y; Ehlert FJ; Zhang Y; Liu-Chen LY
ACS Chem Neurosci; 2020 Oct; 11(19):3036-3050. PubMed ID: 32897695
[TBL] [Abstract][Full Text] [Related]
15. The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys.
Huskinson SL; Platt DM; Zamarripa CA; Dunaway K; Brasfield M; Prisinzano TE; Blough BE; Freeman KB
Pharmacol Biochem Behav; 2022 Jun; 217():173394. PubMed ID: 35513117
[TBL] [Abstract][Full Text] [Related]
16. Renal responses produced by microinjection of the kappa opioid receptor agonist, U50-488H, into sites within the rat lamina terminalis.
Franklin C; Fortepiani L; Nguyen T; Rangel Y; Strong R; Gottlieb HB
Pharmacol Res Perspect; 2015 Mar; 3(2):e00117. PubMed ID: 26038693
[TBL] [Abstract][Full Text] [Related]
17. A pharmacological profile of the novel, peripherally-selective kappa-opioid receptor agonist, EMD 61753.
Barber A; Bartoszyk GD; Bender HM; Gottschlich R; Greiner HE; Harting J; Mauler F; Minck KO; Murray RD; Simon M
Br J Pharmacol; 1994 Dec; 113(4):1317-27. PubMed ID: 7889287
[TBL] [Abstract][Full Text] [Related]
18. Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys.
Ko MC; Willmont KJ; Lee H; Flory GS; Woods JH
Brain Res; 2003 Aug; 982(1):38-44. PubMed ID: 12915238
[TBL] [Abstract][Full Text] [Related]
19. Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.
Zamarripa CA; Naylor JE; Huskinson SL; Townsend EA; Prisinzano TE; Freeman KB
Psychopharmacology (Berl); 2020 May; 237(5):1471-1480. PubMed ID: 32006048
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.
Kaski SW; White AN; Gross JD; Trexler KR; Wix K; Harland AA; Prisinzano TE; Aubé J; Kinsey SG; Kenakin T; Siderovski DP; Setola V
J Pharmacol Exp Ther; 2019 Nov; 371(2):487-499. PubMed ID: 31492823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
